Exelixis
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
1851 Harbor Bay Pkwy, Alameda, Californi...Phone Number
(650) 837-7000Website
www.exelixis.comRevenue
$2.4 BillionStock Symbol
EXELIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
6
7
1
2
2
2
About Exelixis
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan.Explore more
Exelixis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Exelixis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Exelixis
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Exelixis launches new products
Exelixis, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Exelixis has new funding data
Check if Exelixis has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Exelixis recently announced quarterly report
Check out if Exelixis is spiking on competitors!
Click to see if Exelixis had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Exelixis
Find more new buyers
Compare Similar Companies to Exelixis
Compare insights from companies similar to Exelixis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Exelixis
$2.4B
1K - 5K
Public
$118.3M
1994
Christopher SennerExecutive Vice President & Chief Financial Officer
Company Profile Activity
Activity Insights
Exelixis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Exelixis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Exelixis.
Exelixis financials insights
Gather financial insights about Exelixis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2000
Stock Offering
$118.3M
Exelixis Tech Stack
A closer look at the technologies used by Exelixis
See more technologies
Most Recent Scoops
Person-Based
Partnership, Pharmaceuticals, Clinical Operations
Open Position
Open Position
Open Position
Open Position
Exelixis News & Media
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near
Exelixis (NASDAQ:EXEL) remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company’s senior vice president of strategy, said during a session hosted by RBC Capital Markets. Peters said Exelixis’ guidanceExelixis, Inc. (EXEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript
Exelixis, Inc. (EXEL) Stifel 2026 Targeted Oncology Virtual Forum May 20, 2026 1:30 PM EDTCompany ParticipantsAndrew Peters - Senior Vice President of...Exelixis, Inc. (EXEL) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Exelixis, Inc. (EXEL) RBC Capital Markets Global Healthcare Conference 2026 May 19, 2026 9:00 AM EDTCompany ParticipantsAndrew Peters - Senior Vice...Prediction: This Stock Could Double By 2031
It's not the most prominent company in its industry, but it is definitely worth a second look.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Exelixis
Sign Up For FreeTo access detailed company insights
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatm... Read More
